The liver is an excellent target for in vivo gene therapy because hepatocytes are easily accessible to vectors injected into the circulation through large pores in liver capillaries (6) . Nonviral gene delivery vehicles, based on liposomes and DNAprotein complexes, target hepatocytes in vivo, although gene transfer efficiency is low and expression is transient (20, 24) . Recombinant adenoviruses target hepatocytes with higher efficiency but suffer from destructive cellular and blocking humoral immune responses (7, 11, 22) .
Adeno-associated virus (AAV) has shown promise for in vivo gene therapy in a number of organs, such as skeletal muscle, central nervous system, and retina, where expression is efficient, stable, and associated with little inflammation or cellular immune response (1, 4, 5, 10, 12, 21) . Results in the liver have been less consistent, with Snyder et al. providing the most impressive results by achieving sustained and therapeutic levels of factor IX in mice from an AAV vector utilizing a retroviral long terminal repeat (LTR) promoter (18) .
The goal of this study was to further evaluate the potential of AAV as a vector for in vivo gene therapy of the liver. Studies were performed with human ␣-1-antitrypsin (␣-1AT) as a reporter gene in murine models, because it allows quantitation of overall expression of the transgene through enzyme-linked immunosorbent assay (ELISA) of ␣-1AT in serum. Vectors in which ␣-1AT is driven from one of a number of promoters were constructed; they included (i) the 5Ј flanking sequence and upstream enhancer sequences of the albumin gene (Alb), (ii) the 5Ј flanking region of the immediate early gene of cytomegalovirus (CMV), (iii) the 5Ј flanking region of the human phosphoglycerate kinase gene (PGK), (iv) the 5Ј LTR of the Moloney murine leukemia virus, and (v) the chicken ␤-actin promoter fused to the enhancer region of the CMV immediate early gene (CB). Recombinant stocks of AAV for each vector were created by a transfection approach that does not require coinfection with adenovirus.
Hepatocytes were transduced in vivo following infusion of 10 11 genome equivalents of AAV into the portal circulation of immunodeficient mice. Figure 1 shows the level of human ␣-1AT in serum of recipient mice for 18 weeks following gene transfer. The profile of expression with each vector was essentially the same, with the concentration of serum ␣-1AT increasing during the first 6 weeks and thereafter stabilizing for the duration of the experiment. Total production of ␣-1AT was consistent within each group but varied substantially between the different promoters. The highest expression was noted with the albumin and LTR constructs, with levels of ␣-1AT ranging from 5 to 50 g/ml. The CMV enhanced ␤-actin promoter (CB) yielded intermediate levels of ␣-1AT (i.e., 1 to 10 g/ml), whereas expression from the CMV and PGK promoters was substantially lower, at approximately 0.1 to 1 g/ml. Additional experiments conducted with the albumin construct demonstrated a direct relationship between the dose of vector and transgene expression over a range of 3 ϫ 10 8 to 1 ϫ 10 11 vector genomes (data not shown).
The impact of the promoter on the level of transgene expression, noted in our study, may explain some discrepancies in the literature. Two groups failed to demonstrate significant expression of lacZ in the liver with AAV vectors containing the CMV promoter (3, 17) . The performance of the murine leukemia virus LTR is more complex. The high level of activity of the LTR demonstrated in our study is consistent with the data of Snyder et al., who achieved substantial levels of factor IX with a similar vector (18) , but is discordant with the results of Koeberl et al., where expression of alkaline phosphatase and factor IX from the LTR was low (13) .
Additional studies were performed to evaluate the molecular state of the AAV genome in recipients. Livers were harvested from selected animals at 14 weeks after vector infusion and subjected to DNA hybridization analysis, the results of which are presented in Fig. 2 . The total content of proviral DNA in liver was evaluated by digesting cellular DNA with enzymes that release an internal 800-bp fragment followed by DNA hybridization with human ␣-1AT used as a probe ( Fig.  2A) . Proviral DNA was detected in livers from each animal, ranging from approximately 0.1 to 2 proviral copies per diploid genome. Undigested DNA produced a smear without a discrete band (Fig. 2B, lane 1) . DNA restricted with endonucleases that contain a single site within the provirus yielded discrete bands whose apparent molecular weights were equivalent to that of the provirus (Fig. 2B, lanes 2 and 3) . A smaller band of equal intensity was observed when total cellular DNA was restricted with two endonucleases that together release a 3.1-kb internal fragment (Fig. 2B, lane 4) . These data are most consistent with a model in which AAV exists as an integrated head-to-tail concatamer similar to what is seen with latent AAV infection (14, 15, 19) and muscle transduced with AAV vectors (4, 21) .
A number of histological analyses were performed to evaluate the frequency and distribution of AAV transduction fol- lowing intraportal infusion. Immunohistochemical hybridization analysis with an antibody to human ␣-1AT probe revealed staining over ϳ5% of hepatocytes throughout the liver (Fig.  3A to E) that was not found in mock-infected animals (data not shown). More transgene-expressing cells were clustered around central veins ( Fig. 3B and C) than around portal triads ( Fig. 3D and E) . Similar frequency and distribution of transgene-expressing cells were found by in situ hybridization with a probe to human ␣-1AT (Fig. 3F to J) . This does not agree with the findings of Snyder et al., who claimed expression of AAVencoded tyrosine hydroxylase in cells around periportal regions (18) . In our study, the pericentral localization of transduction was observed with each promoter, including the one used by Snyder et al., suggesting that other differences must play a role (e.g., method of delivery). The reasons for the observed gradient of transduction are unclear although not unexpected, considering that many genes demonstrate a gradient of expression along the portal to the central hepatic axis (9) .
Data provided in this report and in the report of Snyder et al. (18) clearly support the use of AAV for targeting to hepatocytes genes that encode secreted proteins. What is the potential of AAV for treatment of metabolic diseases where the hepatocyte serves a catabolic or metabolic function, such as in familial hypercholesterolemia or urea cycle disorders? In situ VOL. 72, 1998 NOTES 10225 hybridization and immunohistochemistry revealed transduction in 5% of hepatocytes following infusion of 10 11 vector genomes of recombinant AAV. Increased catabolic/metabolic capacity would best be achieved if transgene expression was distributed throughout a greater number of hepatocytes. Transgene expression appears to be proportional to dose up to 10 11 vector genomes per injection, suggesting that increased doses will lead to more transduced hepatocytes. Direct confirmation of this hypothesis will require improved methods of AAV production to allow injection of higher vector doses.
In summary, AAV appears to be a viable alternative to adenoviruses and nonviral vectors for in vivo gene therapy to the liver. The advantages of immune evasion that attend their use in muscle (8) need to be confirmed in the liver, although preliminary results in immunocompetent mice suggest that elimination of AAV-transduced hepatocytes by cytotoxic T lymphocytes will not be as much of a problem as has been observed with adenoviruses (data not shown). A better understanding of the mechanism and distribution of proviral integration is needed.
